Serum markers in small cell lung cancer: Opportunities for improvement

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1836, Issue 2, 2013, Pages 255-272

  Harmsma, Marjan ^a   Schutte, Bert ^a   Ramaekers, Frans C S ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Biomarkers; Paraneoplastic disease; Post translational modification; Proteolytic cleavage; Small cell lung cancer; Splicing

Indexed keywords

AUTOANTIBODY; BCR ABL PROTEIN; CALCIUM CHANNEL P TYPE; CALCIUM CHANNEL Q TYPE; CARCINOEMBRYONIC ANTIGEN; CASPASE 3; CASPASE 6; CASPASE 9; CHROMOGRANIN A; CISPLATIN; CREATINE KINASE BB; CYTOKERATIN 18; CYTOKERATIN 19; HU PROTEIN; HYBRID PROTEIN; LACTATE DEHYDROGENASE; MICRORNA; NERVE CELL ADHESION MOLECULE; NEURON SPECIFIC ENOLASE; OXALIPLATIN; PROGASTRIN RELEASING PEPTIDE; SQUAMOUS CELL CARCINOMA ANTIGEN; TISSUE POLYPEPTIDE ANTIGEN; TRANSCRIPTION FACTOR SOX; TRICHOSTATIN A; TUMOR MARKER; VOLTAGE GATED CALCIUM CHANNEL; ZINC FINGER PROTEIN;

ANTIBODY DETECTION; CANCER SCREENING; CIRCULATING TUMOR CELL; DIAGNOSTIC ACCURACY; DISEASE MARKER; EXOSOME; HUMAN; LUNG SMALL CELL CANCER; NEUROENDOCRINE SYSTEM; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PARANEOPLASTIC SYNDROME; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN CLEAVAGE; PROTEIN PROCESSING; REVIEW; RNA SPLICING; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

BIOMARKERS; PARANEOPLASTIC DISEASE; POST-TRANSLATIONAL MODIFICATION; PROTEOLYTIC CLEAVAGE; SMALL CELL LUNG CANCER; SPLICING;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; LUNG NEOPLASMS; PROGNOSIS; SMALL CELL LUNG CARCINOMA;

EID: 84882749681     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2013.06.002     Document Type: Review

References (270)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55:74-108.
2. Pirozynski M. 100years of lung cancer. Respir. Med. 2006, 100:2073-2084.
3. Planque C., Kulasingam V., Smith C.R., Reckamp K., Goodglick L., Diamandis E.P. Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Mol. Cell. Proteomics 2009, 8:2746-2758.
4. American-Cancer-Society Tobacco-related cancers fact sheet. Cancer Facts & Figures 2011 2011.
5. Bray F., Tyczynski J.E., Parkin D.M. Going up or coming down? The changing phases of the lung cancer epidemic from 1967 to 1999 in the 15 European Union countries. Eur. J. Cancer 2004, 40:96-125.
6. Singh S., Pillai S., Chellappan S. Nicotinic acetylcholine receptor signaling in tumor growth and metastasis. J. Oncol. 2011, 2011:456743.
7. Kazarian M., Laird-Offringa I.A. Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy. Mol. Cancer 2011, 10:33.
8. Hecht S.S. More than 500trillion molecules of strong carcinogens per cigarette: use in product labelling?. Tob. Control. 2011, 20:387.
9. Raez L.E., Silva O.E. Lung Cancer: A Practical Guide 2008, Saunders Ltd.
10. Wagner P.L., Kitabayashi N., Chen Y.T., Saqi A. Combined small cell lung carcinomas: genotypic and immunophenotypic analysis of the separate morphologic components. Am. J. Clin. Pathol. 2009, 131:376-382.
11. Ionescu D.N., Treaba D., Gilks C.B., Leung S., Renouf D., Laskin J., Wood-Baker R., Gown A.M. Nonsmall cell lung carcinoma with neuroendocrine differentiation-an entity of no clinical or prognostic significance. Am. J. Surg. Pathol. 2007, 31:26-32.
12. Lyda M.H., Weiss L.M. Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas. Hum. Pathol. 2000, 31:980-987.
13. Cummings J., Ward T.H., Greystoke A., Ranson M., Dive C. Biomarker method validation in anticancer drug development. Br. J. Pharmacol. 2008, 153:646-656.
14. Holdenrieder S., von Pawel J., Dankelmann E., Duell T., Faderl B., Markus A., Siakavara M., Wagner H., Feldmann K., Hoffmann H., Raith H., Nagel D., Stieber P. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Clin. Cancer Res. 2008, 14:7813-7821.
15. Kristjansen P.E., Hansen H.H. Management of small cell lung cancer: a summary of the Third International Association for the Study of Lung Cancer Workshop on Small Cell Lung Cancer. J. Natl. Cancer Inst. 1990, 82:263-266.
16. Moss A.C., Jacobson G.M., Walker L.E., Blake N.W., Marshall E., Coulson J.M. SCG3 transcript in peripheral blood is a prognostic biomarker for REST-deficient small cell lung cancer. Clin. Cancer Res. 2009, 15:274-283.
17. Pedersen N., Mortensen S., Sorensen S.B., Pedersen M.W., Rieneck K., Bovin L.F., Poulsen H.S. Transcriptional gene expression profiling of small cell lung cancer cells. Cancer Res. 2003, 63:1943-1953.
18. Lee C.B., Morris D.E., Fried D.B., Socinski M.A. Current and evolving treatment options for limited stage small cell lung cancer. Curr. Opin. Oncol. 2006, 18:162-172.
19. Turrisi A.T., Kim K., Blum R., Sause W.T., Livingston R.B., Komaki R., Wagner H., Aisner S., Johnson D.H. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N. Engl. J. Med. 1999, 340:265-271.
20. Smit E.F., Groen H.J., Timens W., de Boer W.J., Postmus P.E. Surgical resection for small cell carcinoma of the lung: a retrospective study. Thorax 1994, 49:20-22.
21. Sethi T., Rozengurt E. Multiple neuropeptides stimulate clonal growth of small cell lung cancer: effects of bradykinin, vasopressin, cholecystokinin, galanin, and neurotensin. Cancer Res. 1991, 51:3621-3623.
22. 2+ mobilization and clonal growth. Cancer Res. 1993, 53:5208-5213.
23. Bork E., Hansen M., Urdal P., Paus E., Holst J.J., Schifter S., Fenger M., Engbaek F. Early detection of response in small cell bronchogenic carcinoma by changes in serum concentrations of creatine kinase, neuron specific enolase, calcitonin, ACTH, serotonin and gastrin releasing peptide. Eur. J. Cancer Clin. Oncol. 1988, 24:1033-1038.
24. Carney D.N., Marangos P.J., Ihde D.C., Bunn P.A., Cohen M.H., Minna J.D., Gazdar A.F. Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet 1982, 1:583-585.
25. Lamy P.J., Grenier J., Kramar A., Pujol J.L. Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer. Lung Cancer 2000, 29:197-203.
26. Hansen M., Hammer M., Hummer L. ACTH, ADH, and calcitonin concentrations as markers of response and relapse in small-cell carcinoma of the lung. Cancer 1980, 46:2062-2067.
27. Degorce F., Goumon Y., Jacquemart L., Vidaud C., Bellanger L., Pons-Anicet D., Seguin P., Metz-Boutigue M.H., Aunis D. A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245). Br. J. Cancer 1999, 79:65-71.
28. Song P., Sekhon H.S., Jia Y., Keller J.A., Blusztajn J.K., Mark G.P., Spindel E.R. Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma. Cancer Res. 2003, 63:214-221.
29. Bangur C.S., Switzer A., Fan L., Marton M.J., Meyer M.R., Wang T. Identification of genes over-expressed in small cell lung carcinoma using suppression subtractive hybridization and cDNA microarray expression analysis. Oncogene 2002, 21:3814-3825.
30. Bepler G., Jaques G., Koehler A., Gropp C., Havemann K. Markers and characteristics of human SCLC cell lines. Neuroendocrine markers, classical tumor markers, and chromosomal characteristics of permanent human small cell lung cancer cell lines. J. Cancer Res. Clin. Oncol. 1987, 113:253-259.
31. Zecchini S., Cavallaro U. Neural cell adhesion molecule in cancer: expression and mechanisms. Adv. Exp. Med. Biol. 2008, 663:319-333.
32. Onganer P.U., Seckl M.J., Djamgoz M.B. Neuronal characteristics of small-cell lung cancer. Br. J. Cancer 2005, 93:1197-1201.
33. Titulaer M.J., Wirtz P.W., Willems L.N., van Kralingen K.W., Smitt P.A., Verschuuren J.J. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J. Clin. Oncol. 2008, 26:4276-4281.
34. Sabater L., Titulaer M., Saiz A., Verschuuren J., Gure A.O., Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 2008, 70:924-928.
35. Rozengurt E. Autocrine loops, signal transduction, and cell cycle abnormalities in the molecular biology of lung cancer. Curr. Opin. Oncol. 1999, 11:116-122.
36. Michael M., Babic B., Khokha R., Tsao M., Ho J., Pintilie M., Leco K., Chamberlain D., Shepherd F.A. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J. Clin. Oncol. 1999, 17:1802-1808.
37. Mall J.W., Schwenk W., Philipp A.W., Meyer-Kipker C., Mall W., Muller J., Pollmann C. Serum vascular endothelial growth factor levels correlate better with tumour stage in small cell lung cancer than albumin, neuron-specific enolase or lactate dehydrogenase. Respirology 2002, 7:99-102.
38. Bharti A., Ma P.C., Salgia R. Biomarker discovery in lung cancer-promises and challenges of clinical proteomics. Mass Spectrom. Rev. 2007, 26:451-466.
39. Salven P., Ruotsalainen T., Mattson K., Joensuu H. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int. J. Cancer 1998, 79:144-146.
40. Sher T., Dy G.K., Adjei A.A. Small cell lung cancer. Mayo Clin. Proc. 2008, 83:355-367.
41. Massabki P.S., Silva N.P., Lourenco D.M., Andrade L.E. Neuron specific enolase concentration is increased in serum and decreased in platelets of patients with active systemic sclerosis. J. Rheumatol. 2003, 30:2606-2612.
42. Jaques G., Auerbach B., Pritsch M., Wolf M., Madry N., Havemann K. Evaluation of serum neural cell adhesion molecule as a new tumor marker in small cell lung cancer. Cancer 1993, 72:418-425.
43. Molina R., Auge J.M., Escudero J.M., Marrades R., Vinolas N., Carcereny E., Ramirez J., Filella X. Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE. Tumour Biol. 2008, 29:371-380.
44. Fizazi K., Cojean I., Pignon J.P., Rixe O., Gatineau M., Hadef S., Arriagada R., Baldeyrou P., Comoy E., Le Chevalier T. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma. Cancer 1998, 82:1049-1055.
45. Giovanella L., Piantanida R., Ceriani L., Bandera M., Novario R., Bianchi L., Roncari G. Immunoassay of neuron-specific enolase (NSE) and serum fragments of cytokeratin 19 (CYFRA 21.1) as tumor markers in small cell lung cancer: clinical evaluation and biological hypothesis. Int. J. Biol. Markers 1997, 12:22-26.
46. Jørgensen L.G., Osterlind K., Hansen H.H., Cooper E.H. Serum neuron-specific enolase (S-NSE) in progressive small-cell lung cancer (SCLC). Br. J. Cancer 1994, 70:759-761.
47. Jørgensen L.G., Osterlind K., Genolla J., Gomm S.A., Hernandez J.R., Johnson P.W., Lober J., Splinter T.A., Szturmowicz M. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. Br. J. Cancer 1996, 74:463-467.
48. Shibayama T., Ueoka H., Nishii K., Kiura K., Tabata M., Miyatake K., Kitajima T., Harada M. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung Cancer 2001, 32:61-69.
49. Akoun G.M., Scarna H.M., Milleron B.J., Benichou M.P., Herman D.P. Serum neuron-specific enolase. A marker for disease extent and response to therapy for small-cell lung cancer. Chest 1985, 87:39-43.
50. Takamatsu K., Auerbach B., Gerardy-Schahn R., Eckhardt M., Jaques G., Madry N. Characterization of tumor-associated neural cell adhesion molecule in human serum. Cancer Res. 1994, 54:2598-2603.
51. Niho S., Nishiwaki Y., Goto K., Ohmatsu H., Matsumoto T., Hojo F., Ohe Y., Kakinuma R., Kodama T. Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen. Lung Cancer 2000, 27:159-167.
52. Ebert W., Muley T., Trainer C., Dienemann H., Drings P. Comparison of changes in the NSE levels with clinical assessment in the therapy monitoring of patients with SCLC. Anticancer. Res. 2002, 22:1083-1089.
53. Montero-Hadjadje M., Vaingankar S., Elias S., Tostivint H., Mahata S.K., Anouar Y. Chromogranins A and B and secretogranin II: evolutionary and functional aspects. Acta Physiol. (Oxf.) 2008, 192:309-324.
54. Portela-Gomes G.M., Grimelius L., Stridsberg M., Bresaola E., Viale G., Pelosi G. Expression of amino acid sequences of the chromogranin A molecule and synaptic vesicle protein 2 in neuroendocrine tumors of the lung. Virchows Arch. 2005, 446:604-612.
55. Coulson J.M., Edgson J.L., Woll P.J., Quinn J.P. A splice variant of the neuron-restrictive silencer factor repressor is expressed in small cell lung cancer: a potential role in derepression of neuroendocrine genes and a useful clinical marker. Cancer Res. 2000, 60:1840-1844.
56. Giovanella L., Ceriani L., Bandera M., Garancini S. Immunoradiometric assay of chromogranin A in the diagnosis of small cell lung cancer: comparative evaluation with neuron-specific enolase. Int. J. Biol. Markers 2001, 16:50-55.
57. Nobels F.R., Kwekkeboom D.J., Coopmans W., Schoenmakers C.H., Lindemans J., De Herder W.W., Krenning E.P., Bouillon R., Lamberts S.W. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J. Clin. Endocrinol. Metab. 1997, 82:2622-2628.
58. Børglum T., Rehfeld J.F., Drivsholm L.B., Hilsted L. Processing-independent quantitation of chromogranin a in plasma from patients with neuroendocrine tumors and small-cell lung carcinomas. Clin. Chem. 2007, 53:438-446.
59. Jiang Q., Taupenot L., Mahata S.K., Mahata M., O'Connor D.T., Miles L.A., Parmer R.J. Proteolytic cleavage of chromogranin A (CgA) by plasmin. Selective liberation of a specific bioactive CgA fragment that regulates catecholamine release. J. Biol. Chem. 2001, 276:25022-25029.
60. Biswas N., Vaingankar S.M., Mahata M., Das M., Gayen J.R., Taupenot L., Torpey J.W., O'Connor D.T., Mahata S.K. Proteolytic cleavage of human chromogranin a containing naturally occurring catestatin variants: differential processing at catestatin region by plasmin. Endocrinology 2008, 149:749-757.
61. Metz-Boutigue M.H., Garcia-Sablone P., Hogue-Angeletti R., Aunis D. Intracellular and extracellular processing of chromogranin A. Determination of cleavage sites. Eur. J. Biochem. 1993, 217:247-257.
62. Zhang X.Y., De Meester I., Lambeir A.M., Dillen L., Van Dongen W., Esmans E.L., Haemers A., Scharpe S., Claeys M. Study of the enzymatic degradation of vasostatin I and II and their precursor chromogranin A by dipeptidyl peptidase IV using high-performance liquid chromatography/electrospray mass spectrometry. J. Mass Spectrom. 1999, 34:255-263.
63. Taneja T.K., Sharma S.K. Markers of small cell lung cancer. World J. Surg. Oncol. 2004, 2:10.
64. Drivsholm L., Paloheimo L.I., Osterlind K. Chromogranin A, a significant prognostic factor in small cell lung cancer. Br. J. Cancer 1999, 81:667-671.
65. Pujol J.L., Quantin X., Jacot W., Boher J.M., Grenier J., Lamy P.J. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. Lung Cancer 2003, 39:131-138.
66. Vargas F., Tolosa E., Sospedra M., Catalfamo M., Lucas-Martin A., Obiols G., Pujol-Borrell R. Characterization of neural cell adhesion molecule (NCAM) expression in thyroid follicular cells: induction by cytokines and over-expression in autoimmune glands. Clin. Exp. Immunol. 1994, 98:478-488.
67. Jarahian M., Watzl C., Issa Y., Altevogt P., Momburg F. Blockade of natural killer cell-mediated lysis by NCAM140 expressed on tumor cells. Int. J. Cancer 2007, 120:2625-2634.
68. Shichi K., Fujita-Hamabe W., Harada S., Mizoguchi H., Yamada K., Nabeshima T., Tokuyama S. Involvement of matrix metalloproteinase-mediated proteolysis of neural cell adhesion molecule in the development of cerebral ischemic neuronal damage. J. Pharmacol. Exp. Ther. 2011, 338:701-710.
69. Seidenfaden R., Krauter A., Schertzinger F., Gerardy-Schahn R., Hildebrandt H. Polysialic acid directs tumor cell growth by controlling heterophilic neural cell adhesion molecule interactions. Mol. Cell. Biol. 2003, 23:5908-5918.
70. Lantuejoul S., Moro D., Michalides R.J., Brambilla C., Brambilla E. Neural cell adhesion molecules (NCAM) and NCAM-PSA expression in neuroendocrine lung tumors. Am. J. Surg. Pathol. 1998, 22:1267-1276.
71. Jensen M., Berthold F. Targeting the neural cell adhesion molecule in cancer. Cancer Lett. 2007, 258:9-21.
72. Hosono M.N., Hosono M., Mishra A.K., Faivre-Chauvet A., Gautherot E., Barbet J., Knapp F.F., Chatal J.F. Rhenium-188-labeled anti-neural cell adhesion molecule antibodies with 2-iminothiolane modification for targeting small-cell lung cancer. Ann. Nucl. Med. 2000, 14:173-179.
73. Fidias P., Grossbard M., Lynch T.J. A phase II study of the immunotoxin N901-blocked ricin in small-cell lung cancer. Clin. Lung Cancer 2002, 3:219-222.
74. Klehr M., Koehl U., Muhlenhoff M., Tawadros S., Fischer T., Schomacker K., Heuckmann J.M., Bochennek K., Jensen M. The novel chimeric anti-NCAM (neural cell adhesion molecule) antibody ch.MK1 displays antitumor activity in SCID mice but does not activate complement-dependent cytolysis (CDC). J. Immunother. 2009, 32:442-451.
75. Abidin A.Z., Garassino M.C., Califano R., Harle A., Blackhall F. Targeted therapies in small cell lung cancer: a review. Ther. Adv. Med. Oncol. 2010, 2:25-37.
76. Olsen M., Krog L., Edvardsen K., Skovgaard L.T., Bock E. Intact transmembrane isoforms of the neural cell adhesion molecule are released from the plasma membrane. Biochem. J. 1993, 295(Pt 3):833-840.
77. Secher T. Soluble NCAM. Adv. Exp. Med. Biol. 2010, 663:227-242.
78. Ledermann J.A., Pasini F., Olabiran Y., Pelosi G. Detection of the neural cell adhesion molecule (NCAM) in serum of patients with small-cell lung cancer (SCLC) with "limited" or "extensive" disease, and bone-marrow infiltration. Int. J. Cancer Suppl. 1994, 8:49-52.
79. Cavallaro U., Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat. Rev. Cancer 2004, 4:118-132.
80. Huerta S., Srivatsan E.S., Venkatesan N., Peters J., Moatamed F., Renner S., Livingston E.H. Alternative mRNA splicing in colon cancer causes loss of expression of neural cell adhesion molecule. Surgery 2001, 130:834-843.
81. A. Vanderborght, M.I.J. Ummelen, F.C.S. Ramaekers, S.M. Van den Eijnde, J.L. Broers, F.W. Falkenberg, C. Hahnel, in: vol. patent number US 8133682, MUbio Products BV, 2007.
82. Suzuki M., Angata K., Nakayama J., Fukuda M. Polysialic acid and mucin type o-glycans on the neural cell adhesion molecule differentially regulate myoblast fusion. J. Biol. Chem. 2003, 278:49459-49468.
83. Kochlamazashvili G., Senkov O., Grebenyuk S., Robinson C., Xiao M.F., Stummeyer K., Gerardy-Schahn R., Engel A.K., Feig L., Semyanov A., Suppiramaniam V., Schachner M., Dityatev A. Neural cell adhesion molecule-associated polysialic acid regulates synaptic plasticity and learning by restraining the signaling through GluN2B-containing NMDA receptors. J. Neurosci. 2010, 30:4171-4183.
84. Rygaard K., Moller C., Bock E., Spang-Thomsen M. Expression of cadherin and NCAM in human small cell lung cancer cell lines and xenografts. Br. J. Cancer 1992, 65:573-577.
85. Takada M., Kusunoki Y., Masuda N., Matui K., Yana T., Ushijima S., Iida K., Tamura K., Komiya T., Kawase I., Kikui N., Morino H., Fukuoka M. Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase. Br. J. Cancer 1996, 73:1227-1232.
86. Miyake Y., Kodama T., Yamaguchi K. Pro-gastrin-releasing peptide (31-98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res. 1994, 54:2136-2140.
87. Cho W.C. Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer. Biomed. Pharmacother. 2007, 61:515-519.
88. Nordlund M.S., Bjerner J., Warren D.J., Nustad K., Paus E. Progastrin-releasing peptide: stability in plasma/serum and upper reference limit. Tumour Biol. 2008, 29:204-210.
89. Yoshimura T., Fujita K., Kawakami S., Takeda K., Chan S., Beligere G., Dowell B. Stability of pro-gastrin-releasing peptide in serum versus plasma. Tumour Biol. 2008, 29:224-230.
90. Molina R., Auge J.M., Bosch X., Escudero J.M., Vinolas N., Marrades R., Ramirez J., Carcereny E., Filella X. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. Tumour Biol. 2009, 30:121-129.
91. Kim H.R., Oh I.J., Shin M.G., Park J.S., Choi H.J., Ban H.J., Kim K.S., Kim Y.C., Shin J.H., Ryang D.W., Suh S.P. Plasma proGRP concentration is sensitive and specific for discriminating small cell lung cancer from nonmalignant conditions or non-small cell lung cancer. J. Korean Med. Sci. 2011, 26:625-630.
92. Wójcik E., Kulpa J.K., Sas-Korczynska B., Korzeniowski S., Jakubowicz J. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. Anticancer. Res. 2008, 28:3027-3033.
93. Bubanović G., Pavicevic R., Franjevic A. Determining the cut-off value of pro-gastrin releasing peptide (ProGRP) in lung cancer according to population characteristics. Coll. Antropol. 2008, 32:1155-1164.
94. Molina R., Filella X., Auge J.M. ProGRP: a new biomarker for small cell lung cancer. Clin. Biochem. 2004, 37:505-511.
95. Maruno K., Yamaguchi K., Abe K., Suzuki M., Saijo N., Mishima Y., Yanaihara N., Shimosato Y. Immunoreactive gastrin-releasing peptide as a specific tumor marker in patients with small cell lung carcinoma. Cancer Res. 1989, 49:629-632.
96. Tateishi K., Klee G.G., Cunningham J.M., Lennon V.A. Stability of bombesin in serum, plasma, urine, and culture media. Clin. Chem. 1985, 31:276-278.
97. Yamaguchi K., Abe K., Kameya T., Adachi I., Taguchi S., Otsubo K., Yanaihara N. Production and molecular size heterogeneity of immunoreactive gastrin-releasing peptide in fetal and adult lungs and primary lung tumors. Cancer Res. 1983, 43:3932-3939.
98. Wallimann T., Tokarska-Schlattner M., Schlattner U. The creatine kinase system and pleiotropic effects of creatine. Amino Acids 2011, 40:1271-1296.
99. Carney D.N., Zweig M.H., Ihde D.C., Cohen M.H., Makuch R.W., Gazdar A.F. Elevated serum creatine kinase BB levels in patients with small cell lung cancer. Cancer Res. 1984, 44:5399-5403.
100. Liippo K.K., Terho T. Concomitant monitoring of serum neuron-specific enolase and creatine kinase BB in small cell lung cancer. Acta Oncol. 1991, 30:321-324.
101. Jaques G., Bepler G., Holle R., Wolf M., Hannich T., Gropp C., Havemann K. Prognostic value of pretreatment carcinoembryonic antigen, neuron-specific enolase, and creatine kinase-BB levels in sera of patients with small cell lung cancer. Cancer 1988, 62:125-134.
102. Gazdar A.F., Zweig M.H., Carney D.N., Van Steirteghen A.C., Baylin S.B., Minna J.D. Levels of creatine kinase and its BB isoenzyme in lung cancer specimens and cultures. Cancer Res. 1981, 41:2773-2777.
103. Ariyoshi Y., Kato K., Ueda R., Takahashi T., Sato T., Akatsuka H., Kuwabara M., Kito K., Suchi T., Nishimura M., et al. Biological and clinical implication of neuron-specific enolase and creatine kinase BB in small cell lung cancer. Jpn. J. Clin. Oncol. 1986, 16:213-221.
104. Mercer D.W., Talamo T.S. Multiple markers of malignancy in sera of patients with colorectal carcinoma: preliminary clinical studies. Clin. Chem. 1985, 31:1824-1828.
105. Broers J.L., Carney D.N., de Ley L., Vooijs G.P., Ramaekers F.C. Differential expression of intermediate filament proteins distinguishes classic from variant small-cell lung cancer cell lines. Proc. Natl. Acad. Sci. U. S. A. 1985, 82:4409-4413.
106. Sundstrom B.E., Stigbrand T.I. Cytokeratins and tissue polypeptide antigen. Int. J. Biol. Markers 1994, 9:102-108.
107. Sawaf M.H., Goffaux J.C., Forest N., Ouhayoun J.P. Expression of cytokeratins during embryogenesis and in pathologic epithelia. Pathol. Biol. (Paris) 1992, 40:667-672.
108. Barak V., Goike H., Panaretakis K.W., Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin. Biochem. 2004, 37:529-540.
109. Broers J.L., Ramaekers F.C., Rot M.K., Oostendorp T., Huysmans A., van Muijen G.N., Wagenaar S.S., Vooijs G.P. Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies. Cancer Res. 1988, 48:3221-3229.
110. Ku N.O., Omary M.B. Effect of mutation and phosphorylation of type I keratins on their caspase-mediated degradation. J. Biol. Chem. 2001, 276:26792-26798.
111. Caulin C., Salvesen G.S., Oshima R.G. Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J. Cell Biol. 1997, 138:1379-1394.
112. Schutte B., Henfling M.E., Verheyen F.K., Li G., Tolstonog G.V., Ramaekers F.C. The caspase-9 derived C-terminal fragment of cytokeratin 18 modulates topoisomerase action. Int. J. Oncol. 2009, 35:625-630.
113. Leers M.P., Kolgen W., Bjorklund V., Bergman T., Tribbick G., Persson B., Bjorklund P., Ramaekers F.C., Bjorklund B., Nap M., Jornvall H., Schutte B. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J. Pathol. 1999, 187:567-572.
114. Schutte B., Henfling M., Kolgen W., Bouman M., Meex S., Leers M.P., Nap M., Bjorklund V., Bjorklund P., Bjorklund B., Lane E.B., Omary M.B., Jornvall H., Ramaekers F.C. Keratin 8/18 breakdown and reorganization during apoptosis. Exp. Cell Res. 2004, 297:11-26.
115. Bivén K., Erdal H., Hagg M., Ueno T., Zhou R., Lynch M., Rowley B., Wood J., Zhang C., Toi M., Shoshan M.C., Linder S. A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis 2003, 8:263-268.
116. Linder S., Havelka A.M., Ueno T., Shoshan M.C. Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett. 2004, 214:1-9.
117. Harmsma M., Gromme M., Ummelen M., Dignef W., Tusenius K.J., Ramaekers F.C. Differential effects of Viscum album extract IscadorQu on cell cycle progression and apoptosis in cancer cells. Int. J. Oncol. 2004, 25:1521-1529.
118. Hou J.M., Greystoke A., Lancashire L., Cummings J., Ward T., Board R., Amir E., Hughes S., Krebs M., Hughes A., Ranson M., Lorigan P., Dive C., Blackhall F.H. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am. J. Pathol. 2009, 175:808-816.
119. Greystoke A., Cummings J., Ward T., Simpson K., Renehan A., Butt F., Moore D., Gietema J., Blackhall F., Ranson M., Hughes A., Dive C. Optimisation of circulating biomarkers of cell death for routine clinical use. Ann. Oncol. 2008, 19:990-995.
120. Hacker S., Lambers C., Pollreisz A., Hoetzenecker K., Lichtenauer M., Mangold A., Niederpold T., Hacker A., Lang G., Dworschak M., Vukovich T., Gerner C., Klepetko W., Ankersmit H.J. Increased soluble serum markers caspase-cleaved cytokeratin-18, histones, and ST2 indicate apoptotic turnover and chronic immune response in COPD. J. Clin. Lab. Anal. 2009, 23:372-379.
121. Yilmaz Y., Dolar E., Ulukaya E., Akgoz S., Keskin M., Kiyici M., Yerci O., Oral A.Y., Gul C.B., Gurel S., Nak S.G., Gulten M. Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C. Med. Sci. Monit. 2009, 15:CR189-193.
122. Dohmoto K., Hojo S., Fujita J., Yang Y., Ueda Y., Bandoh S., Yamaji Y., Ohtsuki Y., Dobashi N., Ishida T., Takahara J. The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA21-1) in human lung cancer cell lines. Int. J. Cancer 2001, 91:468-473.
123. Bodenmüller H., Ofenloch-Hähnle B., Lane E.B., Dessauer A., Bottger V., Donie F. Lung cancer-associated keratin 19 fragments: development and biochemical characterisation of the new serum assay Enzymun-Test CYFRA 21-1. Int. J. Biol. Markers 1994, 9:75-81.
124. Lai R.S., Hsu H.K., Lu J.Y., Ger L.P., Lai N.S. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer. Chest 1996, 109:995-1000.
125. Hillas G., Moschos C., Dimakou K., Vlastos F., Avgeropoulou S., Christakopoulou I., Rasidakis A., Bakakos P. Carcinoembryonic antigen, neuron-specific enolase and cytokeratin fragment 19 (CYFRA 21-1) levels in induced sputum of lung cancer patients. Scand. J. Clin. Lab. Invest. 2008, 68:542-547.
126. Huang M.S., Jong S.B., Tsai M.S., Lin M.S., Chong I.W., Lin H.C., Hwang J.J. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma. Respir. Med. 1997, 91:135-142.
127. Pastor A., Menendez R., Cremades M.J., Pastor V., Llopis R., Aznar J. Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis. Eur. Respir. J. 1997, 10:603-609.
128. Patel J.L., Erickson J.A., Roberts W.L., Grenache D.G. Performance characteristics of an automated assay for the quantitation of CYFRA 21-1 in human serum. Clin. Biochem. 2010, 43:1449-1452.
129. Lüning B., Nilsson U. Sequence homology between tissue polypeptide antigen (TPA) and intermediate filament (IF) proteins. Acta Chem. Scand. B 1983, 37:731-733.
130. Dittadi R., Coradini D., Meo S., Pirronello E., Daidone M.G., Gion M. Tissue polypeptide antigen as a putative indicator of apoptosis. Clin. Chem. 1998, 44:2002-2003.
131. Mellerick D.M., Osborn M., Weber K. On the nature of serological tissue polypeptide antigen (TPA); monoclonal keratin 8, 18, and 19 antibodies react differently with TPA prepared from human cultured carcinoma cells and TPA in human serum. Oncogene 1990, 5:1007-1017.
132. Nathrath W.B., Heidenkummer P., Björklund V., Björklund B. Distribution of tissue polypeptide antigen (TPA) in normal human tissues: Immunohistochemical study on unfixed, methanol-, ethanol-, and formalin-fixed tissues. J. Histochem. Cytochem. 1985, 33:99-109.
133. Buccheri G., Ferrigno D. Prognostic value of the tissue polypeptide antigen in lung cancer. Chest 1992, 101:1287-1292.
134. Björklund B., Björklund V. Specificity and basis of the tissue polypeptide antigen. Cancer Detect. Prev. 1983, 6:41-50.
135. Ferrigno D., Buccheri G., Biggi A. Serum tumour markers in lung cancer: history, biology and clinical applications. Eur. Respir. J. 1994, 7:186-197.
136. Menendez-Botet C.J., Oettgen H.F., Pinsky C.M., Schwartz M.K. A preliminary evaluation of tissue polypeptide antigen in serum or urine (or both) of patients with cancer or benign neoplasms. Clin. Chem. 1978, 24:868-872.
137. Gronowitz J.S., Bergstrom R., Nou E., Pahlman S., Brodin O., Nilsson S., Kallander C.F. Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis. Cancer 1990, 66:722-732.
138. van der Gaast A., van Putten W.L., Oosterom R., Cozijnsen M., Hoekstra R., Splinter T.A. Prognostic value of serum thymidine kinase, tissue polypeptide antigen and neuron specific enolase in patients with small cell lung cancer. Br. J. Cancer 1991, 64:369-372.
139. Buccheri G., Ferrigno D. Serum biomarkers of non-neuron-endocrine origin in small-cell lung cancer: a 16-year study on carcinoembryonic antigen, tissue polypeptide antigen and lactate dehydrogenase. Lung Cancer 2000, 30:37-49.
140. Coligan J.E., Henkart P.A., Todd C.W., Terry W.D. Heterogeneity of the carcinoembryonic antigen. Immunochemistry 1973, 10:591-599.
141. Li J., Dai C.H., Chen P., Wu J.N., Bao Q.L., Qiu H., Li X.Q. Survival and prognostic factors in small cell lung cancer. Med. Oncol. 2010, 27:73-81.
142. Goslin R.H., Skarin A.T., Zamcheck N. Carcinoembryonic antigen. A useful monitor of therapy of small cell lung cancer. JAMA 1981, 246:2173-2176.
143. Bandoh S., Fujita J., Ueda Y., Fukunaga Y., Dohmoto K., Hojo S., Yang Y., Yamaji Y., Takahara J., Ishida T. Expression of carcinoembryonic antigen in peripheral- or central-located small cell lung cancer: its clinical significance. Jpn. J. Clin. Oncol. 2001, 31:305-310.
144. Johnson P.W., Joel S.P., Love S., Butcher M., Pandian M.R., Squires L., Wrigley P.F., Slevin M.L. Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. Br. J. Cancer 1993, 67:760-766.
145. Young C.D., Anderson S.M. Sugar and fat - that's where it's at: metabolic changes in tumors. Breast Cancer Res. 2008, 10:202.
146. Ristow M. Oxidative metabolism in cancer growth. Curr. Opin. Clin. Nutr. Metab. Care 2006, 9:339-345.
147. Fantin V.R., St-Pierre J., Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006, 9:425-434.
148. Tas F., Aydiner A., Topuz E., Camlica H., Saip P., Eralp Y. Factors influencing the distribution of metastases and survival in extensive disease small cell lung cancer. Acta Oncol. 1999, 38:1011-1015.
149. Sagman U., Feld R., Evans W.K., Warr D., Shepherd F.A., Payne D., Pringle J., Yeoh J., DeBoer G., Malkin A., et al. The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer. J. Clin. Oncol. 1991, 9:954-961.
150. Watine J. Laboratory variables as additional staging parameters in patients with small-cell lung carcinoma. A systematic review. Clin. Chem. Lab. Med. 1999, 37:931-938.
151. Stokkel M.P., van Eck-Smit B.L., Zwinderman A.H., Willems L.N., Pauwels E.K. Pretreatment serum LDH as additional staging parameter in small-cell lung carcinoma. Neth. J. Med. 1998, 52:65-70.
152. Stokkel M.P., Van Eck-Smit B.L., Zwinderman A.H., Willems L.N., Pauwels E.K. The diagnostic value of pretreatment serum LDH in patients with limited disease small-cell lung carcinoma. Int. J. Biol. Markers 1997, 12:162-167.
153. Vidalino L., Doria A., Quarta S., Zen M., Gatta A., Pontisso P. SERPINB3, apoptosis and autoimmunity. Autoimmun. Rev. 2009, 9:108-112.
154. Murakami A., Fukushima C., Yositomi K., Sueoka K., Nawata S., Fujimoto M., Nakamura K., Sugino N. Tumor-related protein, the squamous cell carcinoma antigen binds to the intracellular protein carbonyl reductase. Int. J. Oncol. 2010, 36:1395-1400.
155. Suminami Y., Nagashima S., Vujanovic N.L., Hirabayashi K., Kato H., Whiteside T.L. Inhibition of apoptosis in human tumour cells by the tumour-associated serpin, SCC antigen-1. Br. J. Cancer 2000, 82:981-989.
156. Body J.J., Sculier J.P., Raymakers N., Paesmans M., Ravez P., Libert P., Richez M., Dabouis G., Lacroix H., Bureau G., et al. Evaluation of squamous cell carcinoma antigen as a new marker for lung cancer. Cancer 1990, 65:1552-1556.
157. Upham J., Campbell B. Utility of squamous cell carcinoma antigen (SCC Ag) as a tumour marker in pulmonary malignancy. Respir. Med. 1992, 86:201-203.
158. Vural B., Chen L.C., Saip P., Chen Y.T., Ustuner Z., Gonen M., Simpson A.J., Old L.J., Ozbek U., Gure A.O. Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters. Cancer 2005, 103:2575-2583.
159. DeLuca I., Blachere N.E., Santomasso B., Darnell R.B. Tolerance to the neuron-specific paraneoplastic HuD antigen. PLoS One 2009, 4:e5739.
160. Hinman M.N., Lou H. Diverse molecular functions of Hu proteins. Cell. Mol. Life Sci. 2008, 65:3168-3181.
161. Deschenes-Furry J., Perrone-Bizzozero N., Jasmin B.J. The RNA-binding protein HuD: a regulator of neuronal differentiation, maintenance and plasticity. Bioessays 2006, 28:822-833.
162. Zhou H.L., Hinman M.N., Barron V.A., Geng C., Zhou G., Luo G., Siegel R.E., Lou H. Hu proteins regulate alternative splicing by inducing localized histone hyperacetylation in an RNA-dependent manner. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:E627-635.
163. Kazarian M., Calbo J., Proost N., Carpenter C.L., Berns A., Laird-Offringa I.A. Immune response in lung cancer mouse model mimics human anti-Hu reactivity. J. Neuroimmunol. 2009, 217:38-45.
164. Verschuuren J.J., Perquin M., ten Velde G., De Baets M., Vriesman P.B., Twijnstra A. Anti-Hu antibody titre and brain metastases before and after treatment for small cell lung cancer. J. Neurol. Neurosurg. Psychiatry 1999, 67:353-357.
165. Tsou J.A., Kazarian M., Patel A., Galler J.S., Laird-Offringa I.A., Carpenter C.L., London S.J. Low level anti-Hu reactivity: a risk marker for small cell lung cancer?. Cancer Detect. Prev. 2009, 32:292-299.
166. Graus F., Dalmou J., Rene R., Tora M., Malats N., Verschuuren J.J., Cardenal F., Vinolas N., Garcia del Muro J., Vadell C., Mason W.P., Rosell R., Posner J.B., Real F.X. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J. Clin. Oncol. 1997, 15:2866-2872.
167. Dalmau J., Furneaux H.M., Gralla R.J., Kris M.G., Posner J.B. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer-a quantitative western blot analysis. Ann. Neurol. 1990, 27:544-552.
168. Monstad S.E., Drivsholm L., Storstein A., Aarseth J.H., Haugen M., Lang B., Vincent A., Vedeler C.A. Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer. J. Clin. Oncol. 2004, 22:795-800.
169. Tschernatsch M., Gross O., Kneifel N., Kaps M., Blaes F. SOX-1 autoantibodies in patients with paraneoplastic neurological syndromes. Autoimmun. Rev. 2009, 8:549-551.
170. Titulaer M.J., Klooster R., Potman M., Sabater L., Graus F., Hegeman I.M., Thijssen P.E., Wirtz P.W., Twijnstra A., Smitt P.A., van der Maarel S.M., Verschuuren J.J. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J. Clin. Oncol. 2009, 27:4260-4267.
171. Güre A.O., Stockert E., Scanlan M.J., Keresztes R.S., Jager D., Altorki N.K., Old L.J., Chen Y.T. Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:4198-4203.
172. Maddison P., Thorpe A., Silcocks P., Robertson J.F., Chapman C.J. Autoimmunity to SOX2, clinical phenotype and survival in patients with small-cell lung cancer. Lung Cancer 2010, 70:335-339.
173. Rudin C.M., Durinck S., Stawiski E.W., Poirier J.T., Modrusan Z., Shames D.S., Bergbower E.A., Guan Y., Shin J., Guillory J., Rivers C.S., Foo C.K., Bhatt D., Stinson J., Gnad F., Haverty P.M., Gentleman R., Chaudhuri S., Janakiraman V., Jaiswal B.S., Parikh C., Yuan W., Zhang Z., Koeppen H., Wu T.D., Stern H.M., Yauch R.L., Huffman K.E., Paskulin D.D., Illei P.B., Varella-Garcia M., Gazdar A.F., de Sauvage F.J., Bourgon R., Minna J.D., Brock M.V., Seshagiri S. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat. Genet. 2012, 44:1111-1116.
174. Cimpean A.M., Encica S., Raica M., Ribatti D. SOX2 gene expression in normal human thymus and thymoma. Clin. Exp. Med. 2010, 11:251-254.
175. Li M., Xiong Z.G. Ion channels as targets for cancer therapy. Int. J. Physiol. Pathophysiol. Pharmacol. 2011, 3:156-166.
176. Oguro-Okano M., Griesmann G.E., Wieben E.D., Slaymaker S.J., Snutch T.P., Lennon V.A. Molecular diversity of neuronal-type calcium channels identified in small cell lung carcinoma. Mayo Clin. Proc. 1992, 67:1150-1159.
177. Codignola A., Tarroni P., Clementi F., Pollo A., Lovallo M., Carbone E., Sher E. Calcium channel subtypes controlling serotonin release from human small cell lung carcinoma cell lines. J. Biol. Chem. 1993, 268:26240-26247.
178. Mason W.P., Graus F., Lang B., Honnorat J., Delattre J.Y., Valldeoriola F., Antoine J.C., Rosenblum M.K., Rosenfeld M.R., Newsom-Davis J., Posner J.B., Dalmau J. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 1997, 120(Pt 8):1279-1300.
179. Grommes C., Preston D.C., Al-Kadhimi Z., Alshekhlee A. Lambert-Eaton syndrome with large-cell neuroendocrine carcinoma of the lung. Muscle Nerve 2008, 37:786-789.
180. Voltz R., Carpentier A.F., Rosenfeld M.R., Posner J.B., Dalmau J. P/Q-type voltage-gated calcium channel antibodies in paraneoplastic disorders of the central nervous system. Muscle Nerve 1999, 22:119-122.
181. Wang S., Bruzzi J., Rodriguez-Garza V.P., Komaki R.R. Lambert-Eaton myasthenic syndrome in a patient with small-cell lung cancer. Clin. Lung Cancer 2006, 7:282-284.
182. Rozsa C., Vincent A., Aranyi Z., Kovacs G.G., Komoly S., Illes Z. Paraneoplastic chronic demyelinating neuropathy and Lambert-Eaton myasthenic syndrome associated with multiple anti-neural antibodies and small-cell lung cancer. Ideggyogy. Sz. 2008, 61:325-328.
183. Bataller L., Wade D.F., Graus F., Stacey H.D., Rosenfeld M.R., Dalmau J. Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology 2004, 62:778-782.
184. Sabater L., Bataller L., Suarez-Calvet M., Saiz A., Dalmau J., Graus F. ZIC antibodies in paraneoplastic cerebellar degeneration and small cell lung cancer. J. Neuroimmunol. 2008, 201-202:163-165.
185. Monstad S.E., Drivsholm L., Skeie G.O., Aarseth J.H., Vedeler C.A. CRMP5 antibodies in patients with small-cell lung cancer or thymoma. Cancer Immunol. Immunother. 2008, 57:227-232.
186. Honnorat J., Cartalat-Carel S., Ricard D., Camdessanche J.P., Carpentier A.F., Rogemond V., Chapuis F., Aguera M., Decullier E., Duchemin A.M., Graus F., Antoine J.C. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J. Neurol. Neurosurg. Psychiatry 2009, 80:412-416.
187. Yu Z., Kryzer T.J., Griesmann G.E., Kim K., Benarroch E.E., Lennon V.A. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann. Neurol. 2001, 49:146-154.
188. Samarasekera S., Rajabally Y.A. Demyelinating neuropathy with anti-CRMP5 antibodies predating diagnosis of breast carcinoma: favorable outcome after cancer therapy. Muscle Nerve 2011, 43:764-766.
189. Meyronet D., Massoma P., Thivolet F., Chalabreysse L., Rogemond V., Schlama A., Honnorat J., Thomasset N. Extensive expression of collapsin response mediator protein 5 (CRMP5) is a specific marker of high-grade lung neuroendocrine carcinoma. Am. J. Surg. Pathol. 2008, 32:1699-1708.
190. Oremek G.M., Sauer-Eppel H., Bruzdziak T.H. Value of tumour and inflammatory markers in lung cancer. Anticancer. Res. 2007, 27:1911-1915.
191. Paone G., De Angelis G., Munno R., Pallotta G., Bigioni D., Saltini C., Bisetti A., Ameglio F. Discriminant analysis on small cell lung cancer and non-small cell lung cancer by means of NSE and CYFRA-21.1. Eur. Respir. J. 1995, 8:1136-1140.
192. Hatzakis K.D., Froudarakis M.E., Bouros D., Tzanakis N., Karkavitsas N., Siafakas N.M. Prognostic value of serum tumor markers in patients with lung cancer. Respiration 2002, 69:25-29.
193. Ando S., Suzuki M., Yamamoto N., Iida T., Kimura H. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer. Anticancer. Res. 2004, 24:1941-1946.
194. Stieber P., Dienemann H., Schalhorn A., Schmitt U.M., Reinmiedl J., Hofmann K., Yamaguchi K. Pro-gastrin-releasing peptide (ProGRP)-a useful marker in small cell lung carcinomas. Anticancer. Res. 1999, 19:2673-2678.
195. Broker L.E., Kruyt F.A., Giaccone G. Cell death independent of caspases: a review. Clin. Cancer Res. 2005, 11:3155-3162.
196. Squìer M.K., Miller A.C., Malkinson A.M., Cohen J.J. Calpain activation in apoptosis. J. Cell. Physiol. 1994, 159:229-237.
197. Lopatniuk P., Witkowski J.M. Conventional calpains and programmed cell death. Acta Biochim. Pol. 2011, 58:287-296.
198. Wee L.J., Tan T.W., Ranganathan S. SVM-based prediction of caspase substrate cleavage sites. BMC Bioinforma. 2006, 7(Suppl. 5):S14.
199. Wee L.J., Tan T.W., Ranganathan S. CASVM: web server for SVM-based prediction of caspase substrates cleavage sites. Bioinformatics 2007, 23:3241-3243.
200. Vandenabeele P., Orrenius S., Zhivotovsky B. Serine proteases and calpains fulfill important supporting roles in the apoptotic tragedy of the cellular opera. Cell Death Differ. 2005, 12:1219-1224.
201. Sheppard A., Wu J., Rutishauser U., Lynch G. Proteolytic modification of neural cell adhesion molecule (NCAM) by the intracellular proteinase calpain. Biochim. Biophys. Acta 1991, 1076:156-160.
202. Covault J., Liu Q.Y., el-Deeb S. Calcium-activated proteolysis of intracellular domains in the cell adhesion molecules NCAM and N-cadherin. Brain Res. Mol. Brain Res. 1991, 11:11-16.
203. Westphal D. NCAM Induces Caspase-3 Activation to Reorganize the Membrane Cytoskeleton to Enhance Neurite Elongation in Mice (Mus musculus L., 1758) 2008, Staats- und Universitätsbibliothek Hamburg, Hamburg.
204. Chan S.L., Mattson M.P. Caspase and calpain substrates: roles in synaptic plasticity and cell death. J. Neurosci. Res. 1999, 58:167-190.
205. Endo A., Nagai N., Urano T., Takada Y., Hashimoto K., Takada A. Proteolysis of neuronal cell adhesion molecule by the tissue plasminogen activator-plasmin system after kainate injection in the mouse hippocampus. Neurosci. Res. 1999, 33:1-8.
206. Endo A., Nagai N., Urano T., Ihara H., Takada Y., Hashimoto K., Takada A. Proteolysis of highly polysialylated NCAM by the tissue plasminogen activator-plasmin system in rats. Neurosci. Lett. 1998, 246:37-40.
207. Kalus I., Bormann U., Mzoughi M., Schachner M., Kleene R. Proteolytic cleavage of the neural cell adhesion molecule by ADAM17/TACE is involved in neurite outgrowth. J. Neurochem. 2006, 98:78-88.
208. Diestel S., Hinkle C.L., Schmitz B., Maness P.F. NCAM140 stimulates integrin-dependent cell migration by ectodomain shedding. J. Neurochem. 2005, 95:1777-1784.
209. Heo J.H., Lucero J., Abumiya T., Koziol J.A., Copeland B.R., del Zoppo G.J. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J. Cereb. Blood Flow Metab. 1999, 19:624-633.
210. Hinkle C.L., Diestel S., Lieberman J., Maness P.F. Metalloprotease-induced ectodomain shedding of neural cell adhesion molecule (NCAM). J. Neurobiol. 2006, 66:1378-1395.
211. Zhao B.Q., Ikeda Y., Ihara H., Urano T., Fan W., Mikawa S., Suzuki Y., Kondo K., Sato K., Nagai N., Umemura K. Essential role of endogenous tissue plasminogen activator through matrix metalloproteinase 9 induction and expression on heparin-produced cerebral hemorrhage after cerebral ischemia in mice. Blood 2004, 103:2610-2616.
212. Kirschbaum N.E., Budzynski A.Z. A unique proteolytic fragment of human fibrinogen containing the A alpha COOH-terminal domain of the native molecule. J. Biol. Chem. 1990, 265:13669-13676.
213. Luo Y., Liang F., Zhang Z.Y. PRL1 promotes cell migration and invasion by increasing MMP2 and MMP9 expression through Src and ERK1/2 pathways. Biochemistry 2009, 48:1838-1846.
214. Saito Y., Tachibana I., Takeda Y., Yamane H., He P., Suzuki M., Minami S., Kijima T., Yoshida M., Kumagai T., Osaki T., Kawase I. Absence of CD9 enhances adhesion-dependent morphologic differentiation, survival, and matrix metalloproteinase-2 production in small cell lung cancer cells. Cancer Res. 2006, 66:9557-9565.
215. Chen E.I., Kridel S.J., Howard E.W., Li W., Godzik A., Smith J.W. A unique substrate recognition profile for matrix metalloproteinase-2. J. Biol. Chem. 2002, 277:4485-4491.
216. Kridel S.J., Chen E., Kotra L.P., Howard E.W., Mobashery S., Smith J.W. Substrate hydrolysis by matrix metalloproteinase-9. J. Biol. Chem. 2001, 276:20572-20578.
217. Meazza R., Verdiani S., Biassoni R., Coppolecchia M., Gaggero A., Orengo A.M., Colombo M.P., Azzarone B., Ferrini S. Identification of a novel interleukin-15 (IL-15) transcript isoform generated by alternative splicing in human small cell lung cancer cell lines. Oncogene 1996, 12:2187-2192.
218. Honda K., Yamada T., Seike M., Hayashida Y., Idogawa M., Kondo T., Ino Y., Hirohashi S. Alternative splice variant of actinin-4 in small cell lung cancer. Oncogene 2004, 23:5257-5262.
219. Chakraborty S., Reineke E.L., Lam M., Li X., Liu Y., Gao C., Khurana S., Kao H.Y. Alpha-actinin 4 potentiates myocyte enhancer factor-2 transcription activity by antagonizing histone deacetylase 7. J. Biol. Chem. 2006, 281:35070-35080.
220. Zhu C., Chen Q., Xie Z., Ai J., Tong L., Ding J., Geng M. The role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-Myc. J. Mol. Med. (Berl.) 2011, 89:279-289.
221. Honda K., Yamada T., Endo R., Ino Y., Gotoh M., Tsuda H., Yamada Y., Chiba H., Hirohashi S. Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion. J. Cell Biol. 1998, 140:1383-1393.
222. Schor I.E., Rascovan N., Pelisch F., Allo M., Kornblihtt A.R. Neuronal cell depolarization induces intragenic chromatin modifications affecting NCAM alternative splicing. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4325-4330.
223. Schor I.E., Kornblihtt A.R. Playing inside the genes: Intragenic histone acetylation after membrane depolarization of neural cells opens a path for alternative splicing regulation. Commun. Integr. Biol. 2009, 2:341-343.
224. Platta C.S., Greenblatt D.Y., Kunnimalaiyaan M., Chen H. The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells. J. Surg. Res. 2007, 142:219-226.
225. Blandino J.K., Viglione M.P., Bradley W.A., Oie H.K., Kim Y.I. Voltage-dependent sodium channels in human small-cell lung cancer cells: role in action potentials and inhibition by Lambert-Eaton syndrome IgG. J. Membr. Biol. 1995, 143:153-163.
226. Pancrazio J.J., Viglione M.P., Tabbara I.A., Kim Y.I. Voltage-dependent ion channels in small-cell lung cancer cells. Cancer Res. 1989, 49:5901-5906.
227. + current in small-cell lung cancer cells. J. Pharmacol. Exp. Ther. 1991, 257:184-191.
228. Krishnan A.V., Goldstein D., Friedlander M., Kiernan M.C. Oxaliplatin and axonal Na+ channel function in vivo. Clin. Cancer Res. 2006, 12:4481-4484.
229. Park S.B., Lin C.S., Krishnan A.V., Goldstein D., Friedlander M.L., Kiernan M.C. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 2009, 132:2712-2723.
230. Stordal B.K., Davey M.W., Davey R.A. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells. Cancer Chemother. Pharmacol. 2006, 58:256-265.
231. Hill A., Bergin P., Hanning F., Thompson P., Findlay M., Damianovich D., McKeage M.J. Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability. BMC Cancer 2010, 10:451.
232. Meguro K., Iida H., Takano H., Morita T., Sata M., Nagai R., Nakajima T. Function and role of voltage-gated sodium channel NaV1.7 expressed in aortic smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H211-219.
233. Jin H., Zangar R.C. Protein modifications as potential biomarkers in breast cancer. Biomark. Insights 2009, 4:191-200.
234. Bafna S., Kaur S., Batra S.K. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene 2010, 29:2893-2904.
235. Krueger K.E., Srivastava S. Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics. Mol. Cell. Proteomics 2006, 5:1799-1810.
236. Zhao Q., Barclay M., Hilkens J., Guo X., Barrow H., Rhodes J.M., Yu L.G. Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. Mol. Cancer 2010, 9:154.
237. Storr S.J., Royle L., Chapman C.J., Hamid U.M., Robertson J.F., Murray A., Dwek R.A., Rudd P.M. The O-linked glycosylation of secretory/shed MUC1 from an advanced breast cancer patient's serum. Glycobiology 2008, 18:456-462.
238. Almogren A., Abdullah J., Ghapure K., Ferguson K., Glinsky V.V., Rittenhouse-Olson K. Anti-Thomsen-Friedenreich-Ag (anti-TF-Ag) potential for cancer therapy. Front. Biosci. (Schol. Ed.) 2012, 1:840-863.
239. Lopez-Ferrer A., Curull V., Barranco C., Garrido M., Lloreta J., Real F.X., de Bolos C. Mucins as differentiation markers in bronchial epithelium. Squamous cell carcinoma and adenocarcinoma display similar expression patterns. Am. J. Respir. Cell Mol. Biol. 2001, 24:22-29.
240. Pesch B., Casjens S., Stricker I., Westerwick D., Taeger D., Rabstein S., Wiethege T., Tannapfel A., Bruning T., Johnen G. NOTCH1, HIF1A and other cancer-related proteins in lung tissue from uranium miners-variation by occupational exposure and subtype of lung cancer. PLoS One 2012, 7:e45305.
241. Figarella-Branger D.F., Durbec P.L., Rougon G.N. Differential spectrum of expression of neural cell adhesion molecule isoforms and L1 adhesion molecules on human neuroectodermal tumors. Cancer Res. 1990, 50:6364-6370.
242. Gluer S., Schelp C., von Schweinitz D., Gerardy-Schahn R. Polysialylated neural cell adhesion molecule in childhood rhabdomyosarcoma. Pediatr. Res. 1998, 43:145-147.
243. Fukuda M. Possible roles of tumor-associated carbohydrate antigens. Cancer Res. 1996, 56:2237-2244.
244. Nilsson O. Carbohydrate antigens in human lung carcinomas. APMIS Suppl. 1992, 27:149-161.
245. Wang Y., Giaccone G. Challenges in cancer molecular targets and therapeutics. Front. Oncol. 2011, 1:4.
246. Goldman J.M., Melo J.V. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001, 344:1084-1086.
247. Albano F., Anelli L., Zagaria A., Coccaro N., Casieri P., Rossi A.R., Vicari L., Liso V., Rocchi M., Specchia G. Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements. Mol. Cancer 2010, 9:120.
248. Wong D.W., Leung E.L., Wong S.K., Tin V.P., Sihoe A.D., Cheng L.C., Au J.S., Chung L.P., Wong M.P. A novel KIF5B-ALK variant in nonsmall cell lung cancer. Cancer 2011, 117:2709-2718.
249. Sasaki T., Rodig S.J., Chirieac L.R., Janne P.A. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur. J. Cancer 2010, 46:1773-1780.
250. Crystal A.S., Shaw A.T. New targets in advanced NSCLC: EML4-ALK. Clin. Adv. Hematol. Oncol. 2011, 9:207-214.
251. Salido M., Pijuan L., Martinez-Aviles L., Galvan A.B., Canadas I., Rovira A., Zanui M., Martinez A., Longaron R., Sole F., Serrano S., Bellosillo B., Wynes M.W., Albanell J., Hirsch F.R., Arriola E. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J. Thorac. Oncol. 2011, 6:21-27.
252. Mäkelä T.P., Shiraishi M., Borrello M.G., Sekiya T., Alitalo K. Rearrangement and co-amplification of L-myc and rlf in primary lung cancer. Oncogene 1992, 7:405-409.
253. Henderson L.J., Coe B.P., Lee E.H., Girard L., Gazdar A.F., Minna J.D., Lam S., MacAulay C., Lam W.L. Genomic and gene expression profiling of minute alterations of chromosome arm 1p in small-cell lung carcinoma cells. Br. J. Cancer 2005, 92:1553-1560.
254. Sekido Y., Takahashi T., Makela T.P., Obata Y., Ueda R., Hida T., Hibi K., Shimokata K., Alitalo K., Takahashi T. Complex intrachromosomal rearrangement in the process of amplification of the L-myc gene in small-cell lung cancer. Mol. Cell. Biol. 1992, 12:1747-1754.
255. Kim J.O., Nau M.M., Allikian K.A., Makela T.P., Alitalo K., Johnson B.E., Kelley M.J. Co-amplification of a novel cyclophilin-like gene (PPIE) with L-myc in small cell lung cancer cell lines. Oncogene 1998, 17:1019-1026.
256. Lee Y., El Andaloussi S., Wood M.J. Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum. Mol. Genet. 2012, 21:R125-134.
257. Grange C., Tapparo M., Collino F., Vitillo L., Damasco C., Deregibus M.C., Tetta C., Bussolati B., Camussi G. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 2011, 71:5346-5356.
258. Hiltermann T.J., Pore M.M., van den Berg A., Timens W., Boezen H.M., Liesker J.J., Schouwink J.H., Wijnands W.J., Kerner G.S., Kruyt F.A., Tissing H., Tibbe A.G., Terstappen L.W., Groen H.J. Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann. Oncol. 2012, 23:2937-2942.
259. Naito T., Tanaka F., Ono A., Yoneda K., Takahashi T., Murakami H., Nakamura Y., Tsuya A., Kenmotsu H., Shukuya T., Kaira K., Koh Y., Endo M., Hasegawa S., Yamamoto N. Prognostic impact of circulating tumor cells in patients with small cell lung cancer. J. Thorac. Oncol. 2012, 7:512-519.
260. Hou J.M., Krebs M.G., Lancashire L., Sloane R., Backen A., Swain R.K., Priest L.J., Greystoke A., Zhou C., Morris K., Ward T., Blackhall F.H., Dive C. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J. Clin. Oncol. 2012, 30:525-532.
261. Ranade A.R., Cherba D., Sridhar S., Richardson P., Webb C., Paripati A., Bowles B., Weiss G.J. MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer. J. Thorac. Oncol. 2010, 5:1273-1278.
262. Du L., Schageman J.J., Irnov L., Girard S.M., Hammond J.D., Minna A.F., Gazdar A. Pertsemlidis, MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs. J. Exp. Clin. Cancer Res. 2009, 29:75.
263. Park J.O., Choi D.Y., Choi D.S., Kim H.J., Kang J.W., Jung J.H., Lee J.H., Kim J., Freeman M.R., Lee K.Y., Gho Y.S., Kim K.P. Identification and characterization of proteins isolated from microvesicles derived from human lung cancer pleural effusions. Proteomics 2013, 13(14):2125-2134.
264. Yu M., Stott S., Toner M., Maheswaran S., Haber D.A. Circulating tumor cells: approaches to isolation and characterization. J. Cell Biol. 2011, 192:373-382.
265. Diamandis E.P. The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?. BMC Med. 2012, 10:87.
266. Greenberg A.K., Lee M.S. Biomarkers for lung cancer: clinical uses. Curr. Opin. Pulm. Med. 2007, 13:249-255.
267. Tockman M.S., Gupta P.K., Pressman N.J., Mulshine J.L. Considerations in bringing a cancer biomarker to clinical application. Cancer Res. 1992, 52:2711s-2718s.
268. Pepe M.S., Etzioni R., Feng Z., Potter J.D., Thompson M.L., Thornquist M., Winget M., Yasui Y. Phases of biomarker development for early detection of cancer. J. Natl. Cancer Inst. 2001, 93:1054-1061.
269. Sajid K.M., Parveen R., Durr-e-Sabih, Chaouachi K., Naeem A., Mahmood R., Shamim R. Carcinoembryonic antigen (CEA) levels in hookah smokers, cigarette smokers and non-smokers. J. Pak. Med. Assoc. 2007, 57:595-599.
270. Bulut I., Arbak P., Coskun A., Balbay O., Annakkaya A.N., Yavuz O., Gulcan E. Comparison of serum CA 19.9, CA 125 and CEA levels with severity of chronic obstructive pulmonary disease. Med. Princ. Pract. 2009, 18:289-293.